Cell Reports · 2014 · 106 citations · 31 references
MedicineMolecular GeneticsOncologyCancer GeneticsCarcinogenesisMolecular OncologyCancer BiomarkersCancer Cell SignalingCancer GenomicsCancer ProgressionLung CancerTumor Suppressor GenesKnockout Mouse ModelsLung Squamous Cell CarcinomaPreclinical Drug DevelopmentPreclinical Drug TestingSomatic Genomic AlterationsTransgenic Mouse ModelsTumor Suppressor LossTumor Suppressor Pathways
Squamous cell carcinoma (SCC) of the lung is the second most common subtype of lung cancer. With limited treatment options, the 5-year survival rate of SCC is only 15%. Although genomic alterations in SCC have been characterized, identifying the alterations that drive SCC is critical for improving treatment strategies. Mouse models of SCC are currently limited. Using lentiviral delivery of Sox2 specifically to the mouse lung, we tested the ability of Sox2 to promote tumorigenesis in multiple tumor suppressor backgrounds. Expression of Sox2, frequently amplified in human SCC, specifically cooperates with loss of Lkb1 to promote squamous lung tumors. Mouse tumors exhibit characteristic histopathology and biomarker expression similar to human SCC. They also mimic human SCCs by activation of therapeutically relevant pathways including STAT and mTOR. This model may be utilized to test the contribution of additional driver alterations in SCC, as well as for preclinical drug discovery.
31
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Core Transcriptional Regulatory Circuitry in Human Embryonic Stem Cells
Laurie A. Boyer, Tong Ihn Lee, Megan F. Cole et al. · Cell · 2005 · 4.5K citations · Full text
Comprehensive genomic characterization of squamous cell lung cancers
Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding, Gad Getz, David A. Wheeler et al. · Nature · 2008 · 2.7K citations · Full text